Literature DB >> 2425029

A surrogate hepatitis B virus antigenic epitope represented by a synthetic peptide and an internal image antiidiotype antibody.

Y M Thanavala, S E Brown, C R Howard, I M Roitt, M W Steward.   

Abstract

The use of molecules that represent single, defined epitopes able to substitute for antigen (i.e. surrogate antigens) offers considerable advantages over the use of native antigen for the precise manipulation of the immune response. We have investigated the immunochemical characteristics of two types of surrogate hepatitis B surface antigen (HBsAg) epitopes: (a) linear and cyclical synthetic peptides representing amino acid residues 139-147, a hydrophilic region corresponding to part of the a determinant of the HBsAg, and (b) four monoclonal antiidiotypes raised against anti-HBs mAb, two of which behave as an internal image of an a determinant. Polyclonal anti-HBs antisera bound the monoclonal antiidiotypes with affinities of the order of 10(8)/M, and to the peptides with greater than 10-fold lower affinities. However, the levels of antibody in the polyclonal antisera for the peptides was greater than for the antiidiotypes. In inhibition RIA, the surrogate antigens show concordance in that the internal image antiidiotypes inhibit the binding of both monoclonal and polyclonal anti-HBs to the linear and cyclical 139-147 peptides. These results imply that surrogate antigens could indeed be useful as potential hepatitis vaccines, but while the antiidiotypes may stimulate B cells of higher affinity, they would react with a more restricted range of B cell reactivities than would the peptides. A future HBV vaccine may thus comprise a synthetic peptide such as cyclical 139-147 or a cluster of monoclonal internal image antiidiotypes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425029      PMCID: PMC2188204          DOI: 10.1084/jem.164.1.227

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

Review 1.  New aspects of vaccine development.

Authors:  F Y Liew
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Idiotypic networks and their possible exploitation for manipulation of the immune response.

Authors:  I M Roitt; A Cooke; D K Male; F C Hay; G Guarnotta; P M Lydyard; L P de Carvalho; Y Thanavala; J Ivanyi
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

Review 4.  Synthetic vaccines.

Authors:  R Arnon; M Shapira; C O Jacob
Journal:  J Immunol Methods       Date:  1983-07-29       Impact factor: 2.303

5.  Production of monoclonal antibodies to hepatitis B surface and core antigens, and use in the detection of viral antigens in liver biopsies.

Authors:  R S Tedder; P Guarascio; J L Yao; R B Lord; A L Eddleston
Journal:  J Hyg (Lond)       Date:  1983-02

6.  Analysis of hepatitis B surface antigen components solubilized with Triton X-100.

Authors:  J Skelly; C R Howard; A J Zuckerman
Journal:  J Gen Virol       Date:  1979-09       Impact factor: 3.891

7.  Quality and safety of human hepatitis B vaccine.

Authors:  M R Hilleman; W J McAleer; E B Buynak; A A McLean
Journal:  Dev Biol Stand       Date:  1983

8.  Human hepatitis B vaccine from recombinant yeast.

Authors:  W J McAleer; E B Buynak; R Z Maigetter; D E Wampler; W J Miller; M R Hilleman
Journal:  Nature       Date:  1984 Jan 12-18       Impact factor: 49.962

Review 9.  Synthetic peptide immunogens as vaccines.

Authors:  T M Shinnick; J G Sutcliffe; N Green; R A Lerner
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

10.  Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; H J Alter; P E Taylor; A DeVera; G T Chen; A Kellner
Journal:  N Engl J Med       Date:  1982-12-09       Impact factor: 91.245

View more
  2 in total

1.  Immunity to hepatitis B: analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and pre-S regions.

Authors:  M W Steward; B M Sisley; C Stanley; S E Brown; C R Howard
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

Review 2.  Idiotypic vaccines and infectious diseases.

Authors:  J R Hiernaux
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.